Engineering antibodies with Fc regions of the IgE class specific for cancer antigens is designed to (i) harness the high affinity of this antibody isotype for its cognate Fcε receptors on tissue‐resident and potentially tumour‐resident immune effector cells and (ii) utilize the properties of IgE to exert immune surveillance in Th2 conditions such as in tumour microenvironments. Here, IGHE is linked to neoplasm.